Tianjin Lisheng Pharmaceutical (002393.SZ): The application for the listing permit of Apimist tablets has been approved.

16:06 12/12/2025

Lisheng Pharmaceutical (002393.SZ) announced that its subsidiary, Tianjin Central Pharmaceutical Co., Ltd. (referred to as "Central Pharmaceutical"), has received the "Drug Registration Certificate" for the 10mg specification of Apomisartan tablets, the "Drug Registration Certificate" for the 20mg specification of Apomisartan tablets, and the "Drug Registration Certificate" for the 30mg specification of Apomisartan tablets issued by the National Medical Products Administration. The above-mentioned drugs have passed the drug market authorization application.

Tianjin Lisheng Pharmaceutical (002393.SZ) announced that its subsidiary Tianjin Zhongyang Pharmaceutical Co., Ltd. ("Zhongyang Pharmaceutical") has received the "Drug Registration Certificate" for 10mg, 20mg, and 30mg specifications of Apmisartan tablets issued by the National Medical Products Administration. The above-mentioned drugs have passed the drug marketing approval application. According to the announcement, the indications for Apmisartan tablets are: This product is used to treat adult patients with moderate to severe plaque psoriasis who meet the indications for phototherapy or systemic treatment.

Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.

US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.

Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families

Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.

US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.

Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families